MRC1 and neoplasm: Moreover, liver metastases from CRC patients that respond to neoadjuvant chemotherapy significantly alter the spatiotemporal landscape of MRC1+CCL18+ M2 macrophages that are otherwise absent in non-responders, highlighting the identification of patient subsets that may benefit from combination immunotherapies that selectively target these tumour-promoting immune cells [172].